Abstract
Many ethical issues surround the provision of fertility preservation for patients diagnosed with cancer. Three of the most common questions—who should be offered or undergo fertility preservation procedures, who should pay for those procedures, and the ownership of the resulting banked reproductive materials—are discussed in detail in this chapter. Patient age, marital status, and prognosis are important issues that must be considered when determining who should undergo fertility preservation procedures. A case is made for insurance coverage of fertility preservation for cancer patients, as infertility is a consequence of cancer treatment. Finally, the complex legal issues with regard to ownership of gametes (eggs, sperm), embryos, and gonadal tissue that are banked as a result of fertility preservation procedures are discussed, as well as approaches to preventing disputes over reproductive material, such as the use of advance directives. Clinicians will need to anticipate these ethical issues and their patients’ questions and consider each patient’s individual needs and circumstances in order to provide appropriate care.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Woodruff TK. The Oncofertility Consortium—addressing fertility in young people with cancer. Nat Rev Clin Oncol. 2010;7:466–75.
Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol. 2004;103:51–6.
Committee on Gynecologic Practice of American College of Obstetricians and Gynecologists; Practice Committee of American Society for Reproductive Medicine. Age-related fertility decline: a committee opinion. Fertil Steril. 2008;90:S154–5.
Garrido N, et al. Cumulative live-birth rates per total number of embryos needed to reach newborn in consecutive in vitro fertilization (IVF) cycles: a new approach to measuring the likelihood of IVF success. Fertil Steril. 2011;96:40–6.
Caplan AL, Patrizio P. Are you ever too old to have a baby? The ethical challenges of older women using infertility services. Semin Reprod Med. 2010;28:281–6.
Maltaris T, et al. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol. 2006;103:1109–21.
Quinn GP, et al. Frozen hope: fertility preservation for women with cancer. J Midwifery Womens Health. 2010;55:175–80.
Robinson BE. Birds do it. Bees do it. So why not single women and lesbians? Bioethics. 1997;11:217–27.
Basco D, Campo-Engelstein L, Rodriguez S. Insuring against infertility: expanding state infertility mandates to include fertility preservation technology for cancer patients. J Law Med Ethics. 2010;38:832–9.
Campo-Engelstein L. Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. J Clin Oncol. 2010;28:1284–6.
Campo-Engelstein L. For the sake of consistency and fairness: why insurance companies should cover fertility preservation treatment for iatrogenic infertility. Cancer Treat Res. 2010;156:381–8.
Fertile Hope. Financial assistance. 2011. http://www.fertilehope.org/financial-assistance/index.cfm. Accessed 2 Aug 2011.
Smith K. Cost of fertility preservation treatment at Northwestern University, Campo-Engelstein L, editor. 2011 (Personal communication).
Chambers GM, et al. The economic impact of assisted reproductive technology: a review of selected developed countries. Fertil Steril. 2009;91:2281–94.
Elster NR. Assisted reproductive technologies: contracts, consents, and controversies. Am J Fam Law. 2005;18:193–9.
Kingdregan CP, Snyder SH. Clarifying the law of ART: the new American Bar Association model act governing assisted reproductive technology. Fam Law Q. 2008;42:203–29.
Fuselier BM. The trouble with putting all of your eggs in one basket: using a property rights model to resolve disputes over cryopreserved pre-embryos. Texas J Civil Lib Civil Rights. 2009;14:143–91.
National Organ Transplantation Act, 42 USC §273 (1984).
Campo-Engelstein L. Gametes or organs? How should we legally classify ovaries used for transplantation in the USA? J Med Ethics. 2011;37:166–70.
Acknowledgments
This work was supported by the Oncofertility Consortium NIH/NICHD 5UL1DE019587.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Campo-Engelstein, L. (2012). Addressing the Three Most Frequently Asked Questions of a Bioethicist in an Oncofertility Setting. In: Gracia, C., Woodruff, T. (eds) Oncofertility Medical Practice. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9425-7_9
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9425-7_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9424-0
Online ISBN: 978-1-4419-9425-7
eBook Packages: MedicineMedicine (R0)